References
1. Fraticelli P, Benfaremo D, Gabrielli A. Diagnosis and management of leukocytoclastic vasculitis. Intern Emerg Med.2021;16(4):831-841.
2. Guevara-Rodriguez N, Flores-Chang M, Chilakala A, Contreras J, Perdomo P, Liliya G. A rare adverse event of atorvastatin inducing leukocytoclastic vasculitis with ANCA-negative (Anti-Neutrophil cytoplasmic antibody) case report and literature review. Clin Case Rep. 2023;11(3):e7030.
3. Knowles S, Gupta AK, Shear NH. The spectrum of cutaneous reactions associated with diltiazem: three cases and a review of the literature.J Am Acad Dermatol. 1998;38(2 Pt 1):201-206.
4. Ouni B, Fathallah N, Ben-Sayed N, et al. Enalapril-lercanidipine combination induced leukocytoclastic vasculitis: A case report. Br J Clin Pharmacol. 2021;87(1):210-211.
5. Sheoran A, Mahto SK, Verma P, War GA, Agarwal N, Singh A. Leukocytoclastic vasculitis: An uncommon adverse effect of a common drug. J Family Med Prim Care. 2019;8(6):2137-2139.
6. Stern R, Khalsa JH. Cutaneous adverse reactions associated with calcium channel blockers. Arch Intern Med. 1989;149(4):829-832.
7. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther.1981;30(2):239-245.
8. Choi DH, Shin WG, Choi JS. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. Eur J Clin Pharmacol. 2008;64(5):445-449.
9. Yap BJM, Lai-Foenander AS, Goh BH, et al. Unraveling the Immunopathogenesis and Genetic Variants in Vasculitis Toward Development of Personalized Medicine. Front Cardiovasc Med. 2021;8:732369.
10. Silva F, Pinto C, Barbosa A, Borges T, Dias C, Almeida J. New insights in cryoglobulinemic vasculitis. J Autoimmun.2019;105:102313.